Application of stem cell exosome in preparation of drug for resisting colitis deterioration

Abstract

The invention provides application of a stem cell exosome in preparation of a drug for resisting colitis deterioration. A mouse colorectal cancer (CRC) model is induced in an AOM / DSS combined induction manner, the mouse weight, disease activity index (DAI), colorectal tissue pathologic structure and colorectal tissue deterioration degree are detected, and results show that the exosome derived fromhuman umbilical cord mesenchymal stem cells (hucMSCs) can inhibit the colorectal deterioration process. The invention belongs to biotherapy, and the exosome delays or inhibits the colitis deterioration process of a model animal by inhibiting expression of SUMO1 protein, has the characteristics of low immunogenicity, source convenience and the like and has good application prospects in resisting the colitis deterioration process.

Description

technical field

[0001] The invention relates to the field of medical biotechnology, in particular to the application of stem cell exosomes in the preparation of anti-colitis exacerbation drugs. Background technique

[0002] Colorectal cancer (CRC) is a malignant tumor of the digestive tract with a high incidence in humans and the third most common malignant tumor in the world. Repeated damage, repair and proliferation of chronic inflammation can easily cause gene mutation and cell canceration. Studies have shown that about 25% of cancers are derived from chronic inflammation. For example, inflammatory bowel disease (IBD) is an important pathogenic factor of colorectal cancer, a large Increased risk of colorectal cancer. Thus, effective treatment of colonic inflammation is of great significance for the prevention of colorectal cancer.

[0003] Currently there is no therapeutic approach against malignant transformation of colitis, and the main focus is on monitoring and prev...

Images